JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Premier Inc

Slēgts

SektorsVeselības aprūpe

21.69 -0.09

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

21.49

Max

21.77

Galvenie mērījumi

By Trading Economics

Ienākumi

32M

-14M

Pārdošana

21M

261M

P/E

Sektora vidējais

20.706

40.048

Dividenžu ienesīgums

3.97

Peļņas marža

-5.414

Darbinieki

2,900

EBITDA

139M

76M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+2.63% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.97%

2.45%

Nākamie ieņēmumi

2025. g. 19. aug.

Nākamais dividenžu datums

2025. g. 12. sept.

Nākamais Ex dividenžu datums

2025. g. 29. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

640

1.9B

Iepriekšējā atvēršanas cena

21.78

Iepriekšējā slēgšanas cena

21.69

Ziņu noskaņojums

By Acuity

50%

50%

175 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

Premier Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. aug. 21:42 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

2025. g. 4. aug. 21:21 UTC

Peļņas
Galvenie tirgus virzītāji

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

2025. g. 4. aug. 20:45 UTC

Peļņas

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

2025. g. 4. aug. 19:15 UTC

Galvenie tirgus virzītāji

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

2025. g. 4. aug. 23:41 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 4. aug. 23:41 UTC

Tirgus saruna

Nikkei May Rise on Fed Stimulus Hopes

2025. g. 4. aug. 23:28 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 4. aug. 23:28 UTC

Tirgus saruna

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

2025. g. 4. aug. 21:30 UTC

Peļņas

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025. g. 4. aug. 21:21 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

2025. g. 4. aug. 21:18 UTC

Peļņas

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025. g. 4. aug. 20:25 UTC

Tirgus saruna

India Hits Back Over Russian Oil Purchases -- Market Talk

2025. g. 4. aug. 20:25 UTC

Peļņas

Transocean 2Q Loss $938M >RIG

2025. g. 4. aug. 20:25 UTC

Peļņas

Transocean 2Q Loss/Shr $1.06 >RIG

2025. g. 4. aug. 20:18 UTC

Peļņas

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

2025. g. 4. aug. 20:15 UTC

Peļņas

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

2025. g. 4. aug. 20:14 UTC

Peļņas

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

2025. g. 4. aug. 20:14 UTC

Peļņas

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

2025. g. 4. aug. 20:14 UTC

Peļņas

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

2025. g. 4. aug. 20:13 UTC

Peļņas

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

2025. g. 4. aug. 20:09 UTC

Peļņas

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

2025. g. 4. aug. 20:06 UTC

Peļņas

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

2025. g. 4. aug. 19:41 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower -- Market Talk

2025. g. 4. aug. 19:28 UTC

Tirgus saruna

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

2025. g. 4. aug. 19:07 UTC

Tirgus saruna

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

2025. g. 4. aug. 18:27 UTC

Tirgus saruna

Gold Climbs on Rate Cut Speculation -- Market Talk

Salīdzinājums

Cenas izmaiņa

Premier Inc Prognoze

Cenas mērķis

By TipRanks

2.63% augšup

Prognoze 12 mēnešiem

Vidējais 21.83 USD  2.63%

Augstākais 24 USD

Zemākais 19 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Premier Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

7 ratings

0

Pirkt

6

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

20.38 / N/AAtbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

175 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Premier Inc

Premier, Inc., together with its subsidiaries, operates as a healthcare improvement company in the United States. It operates in two segments, Supply Chain Services and Performance Services. The Supply Chain Services segment offers its members with an access to a range of products and services, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, and food and nutritional products, as well as purchased services, such as clinical engineering and workforce solutions. This segment also provides the ASCENDrive programs for members to receive group purchasing programs, tiers, and prices; SURPASS Performance Group services for coordinate purchasing decisions, review utilization and achieve and maintain standardization across member's facilities; SaaS informatics products for the purchase additional elements; supply chain co-management services; purchased services contracts; direct sourcing solutions; and supply chain resiliency programs. The Performance Services segment provides technology and services platform with offerings that help optimize performance in three main areas, including clinical intelligence, margin improvement, and value-based care under the PINC AI brand; third party administrator services and management of health benefit programs under the Contigo Health brand; and digital invoicing and payables services that offers financial support services to healthcare product suppliers and service providers under the Remitra brand. The company was incorporated in 2013 and is headquartered in Charlotte, North Carolina.